The value of knowing is not always positive

An interesting article by Ciancio et al. (2025) which examines the impact of learning one has HIV when no treatment is available. When there is no treatment available for a life-threatening disease, providing personal health information could lead to despair or fatalistic behaviors resulting in negative health outcomes. We document this possibility utilizing an experiment…

Read More

You’re Not Going to Automate MY Job

By KIM BELLARD Earlier this month U.S. dockworkers struck, for the first time in decades. Their union, the International Longshoremen’s Association (ILW), was demanding a 77% pay increase, rejecting an offer of a 50% pay increase from the shipping companies. People worried about the impact on the economy, how it might impact the upcoming election,…

Read More

BioMarin’s Presence in Rare Enzyme Disorders Grows With $4.8B Amicus Therapeutics Acquisition

BioMarin Pharmaceutical’s acquisition of Amicus Therapeutics is a marriage of two rare disease biotech companies. Amicus’s two commercialized products, for the enzyme deficiencies Fabry disease and Pompe disease, are each projected to become blockbuster sellers. The post BioMarin’s Presence in Rare Enzyme Disorders Grows With $4.8B Amicus Therapeutics Acquisition appeared first on MedCity News.

Read More